Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage

72 kDa Type IV Collagese (Matrix Metalloproteise 2 or Gelatise A or Neutrophil Gelatise or 72 kDa Gelatise or TBE 1 or MMP2 or EC 3.4.24.24) - Overview

72 kDa Type IV Collagese (Matrix Metalloproteise 2 or Gelatise A or Neutrophil Gelatise or 72 kDa Gelatise or TBE 1 or MMP2 or EC 3.4.24.24) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes

72 kDa Type IV Collagese (Matrix Metalloproteise 2 or Gelatise A or Neutrophil Gelatise or 72 kDa Gelatise or TBE 1 or MMP2 or EC 3.4.24.24) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type

72 kDa Type IV Collagese (Matrix Metalloproteise 2 or Gelatise A or Neutrophil Gelatise or 72 kDa Gelatise or TBE 1 or MMP2 or EC 3.4.24.24) - Companies Involved in Therapeutics Development
NeuroMax Ltd
Pharmahungary 2000 Kft

72 kDa Type IV Collagese (Matrix Metalloproteise 2 or Gelatise A or Neutrophil Gelatise or 72 kDa Gelatise or TBE 1 or MMP2 or EC 3.4.24.24) - Drug Profiles
AQU-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AQU-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AQU-118 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Carbonic Anhydrases and MMPs for Metastatic Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MMP 2,9 and 13 for Myocardial Infarction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target MMP2 and MMP9 for Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

72 kDa Type IV Collagese (Matrix Metalloproteise 2 or Gelatise A or Neutrophil Gelatise or 72 kDa Gelatise or TBE 1 or MMP2 or EC 3.4.24.24) - Dormant Products

72 kDa Type IV Collagese (Matrix Metalloproteise 2 or Gelatise A or Neutrophil Gelatise or 72 kDa Gelatise or TBE 1 or MMP2 or EC 3.4.24.24) - Discontinued Products

72 kDa Type IV Collagese (Matrix Metalloproteise 2 or Gelatise A or Neutrophil Gelatise or 72 kDa Gelatise or TBE 1 or MMP2 or EC 3.4.24.24) - Product Development Milestones
Featured News & Press Releases
Nov 07, 2018: California research team publishes promising results from peptide based universal cancer vaccine
Jun 28, 2016: NeuroMax Announces Start Phase 1 Clinical Trial of AQU-005 for the Treatment of Neuropathic Pain
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019


List of Tables


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indication, H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by NeuroMax Ltd, H1 2019
Pipeline by Pharmahungary 2000 Kft, H1 2019
Dormant Products, H1 2019
Dormant Products, H1 2019 (Contd..1), H1 2019
Dormant Products, H1 2019 (Contd..2), H1 2019
Discontinued Products, H1 2019